William Blair Reiterates Outperform Rating on Rocket Pharmaceuticals (RCKT)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
JPMorgan Downgrades Rocket Pharmaceuticals (RCKT) to Neutral
May 28, 2025 3:07 PM EDTJPMorgan analyst Eric Joseph downgraded Rocket Pharmaceuticals (NASDAQ: RCKT) from Overweight to Neutral with a price target of $7.00 (from $44.00).
The analyst comments "We are downgrading RCKT shares to Neutral from Overweight on the back of yesterdays announced clinical hold on lead program RP-A501... More
Goldman Sachs Downgrades Rocket Pharmaceuticals (RCKT) to Sell
May 28, 2025 9:35 AM EDTGoldman Sachs analyst Richard Law downgraded Rocket Pharmaceuticals (NASDAQ: RCKT) from Buy to Sell with a price target of $2.00 (from $13.00).
The analyst comments "On Tuesday (5/27), RCKT announced that the FDA placed a clinical hold on its pivotal Ph. 2 Danon disease (DD) trial. The hold was issued on 5/23 after a patient treated in early May experienced capillary... More
Rocket Pharmaceuticals (RCKT) PT Lowered to $9 at BofA Securities
May 28, 2025 5:13 AM EDTBofA Securities analyst Greg Harrison lowered the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $9.00 (from $32.00) while maintaining a Buy rating.
The analyst comments "Rockets announcement of a death in its RP-A501 phase 2 for rare disorder Danon is tragic on... More
BMO Capital on Rocket Pharmaceuticals (RCKT): 'we expect today's announcement...to significantly pressure RCKT'
May 27, 2025 8:10 AM EDTBMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $30.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT).
The analyst comments "Mgt announced a patient death in Danon trial following capillary leak syndrome sAE, triggering a clinical hold by the FDA. Importantly, the event... More
Jefferies on Rocket Pharmaceuticals (RCKT): 'We expect significant stock weakness'
May 27, 2025 8:07 AM EDTJefferies analyst Andrew Tsai reiterated a Buy rating and $29.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT).
The analyst comments "We expect significant stock weakness as a Danon patient died due to an acute systemic infection (following an SAE), leading the... More
Rocket Pharmaceuticals (RCKT) PT Lowered to $32 at BofA Securities
May 27, 2025 8:06 AM EDTBofA Securities analyst Greg Harrison lowered the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $32.00 (from $34.00) while maintaining a Buy rating.
The analyst comments "While Rockets incremental 1Q update was likely overshadowed by its late-breaker oral at ASGCT (see below), we were nonetheless encouraged by the progress and continue to like the 2H setup. GAAP EPS was modestly ahead of BB cons (+$0.02), but more... More
Morgan Stanley on Rocket Pharmaceuticals (RCKT): 'we expect RCKT shares to be under significant pressure today'
May 27, 2025 8:05 AM EDTMorgan Stanley analyst Michael E Ulz reiterated an Overweight rating and $42.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT).
The analyst comments "Ph2 pivotal Danon study on clinical hold due to SAE and subsequent patient death. Rocket announced (PR here) that it had voluntarily paused dosing in its Ph2 study of RP-A501, its AAV9-based gene therapy for the... More
JPMorgan on Rocket Pharmaceuticals (RCKT): 'we wouldn’t be surprised by shares continuing to be under pressure'
May 27, 2025 8:04 AM EDTJPMorgan analyst Eric Joseph reiterated an Overweight rating and $44.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT).
The analyst comments "In our view, this mornings announcement of a patient death in the pivotal phase 2 study of RP-A501 for Danon Disease and subsequent FDA placed clinical hold represents a major, perhaps... More
Rocket Pharmaceuticals (RCKT) Provides Update on Phase 2 Trial of RP-A501
May 27, 2025 7:01 AM EDTRocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing an integrated pipeline of genetic therapies for rare diseases, today announced an update related to RP-A501, its investigational gene therapy for Danon disease.
A patient participating in the Phase 2 pivotal trial of RP-A501... More
